Inrebic® (fedratinib) – New orphan drug approval
August 16, 2019 - The FDA announced the approval of Celgene’s Inrebic (fedratinib), for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Top